Animal venoms are the subject of study at the Butantan Institute in São Paulo. But in this case, the idea is not to find antidotes, but rather to use the properties of the venoms themselves to identify molecular targets ...
Feb 15, 2019
0
0
Of the 38 million Americans who have diabetes, at least 90% have type 2, according to the Centers for Disease Control and Prevention. Type 2 diabetes occurs over time and is characterized by a loss of the cells in the pancreas ...
Feb 29, 2024
0
17
A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist ...
Jan 25, 2013
0
1
Health workers may soon have a new weapon in the fight against abscesses—difficult-to-treat bacterial infections that lead to millions of emergency-room visits every year.
Sep 28, 2016
0
1
A synthetic peptide developed by researchers at the Medical College of Georgia could help reduce vascular problems associated with acute respiratory distress syndrome (ARDS) in COVID-19.
Oct 3, 2023
0
23
Canadian health and wellness company PreveCeutical Medical Inc. (PMI) has signed a research and option agreement with UniQuest, The University of Queensland's main commercialisation company, to develop stabilised natural ...
Apr 21, 2017
0
1
Scientists from Nanyang Technological University (NTU) and Lund University, Sweden, have bioengineered a novel molecule which has been proven to successfully kill tumour cells.
May 21, 2013
0
0
Brazilian researchers who study a native venomous fish have confirmed a route to drug development for the treatment of chronic inflammatory diseases such as multiple sclerosis and asthma.
Mar 9, 2021
0
15
Signal molecules called chemokines often work in tandem to recruit specific sets of immune cells to sites of tissue damage. A systematic analysis of their interactions by researchers from Ludwig-Maximilians-Universitaet (LMU) ...
Apr 6, 2017
0
0
(Edmonton) Researchers at the University of Alberta have developed a synthetic peptide that could be the first in a new class of drugs to treat heart disease, high blood pressure and diabetes.
Sep 17, 2013
0
0
